Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Net Income towards Common Stockholders (2022 - 2025)

Oramed Pharmaceuticals' Net Income towards Common Stockholders history spans 4 years, with the latest figure at $72.9 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders changed N/A year-over-year to $72.9 million; the TTM value through Dec 2025 reached $126.9 million, changed N/A, while the annual FY2025 figure was $64.0 million, 435.11% up from the prior year.
  • Net Income towards Common Stockholders reached $72.9 million in Q4 2025 per ORMP's latest filing, up from $48.4 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $72.9 million in Q4 2025 to a low of -$19.6 million in Q3 2024.
  • Average Net Income towards Common Stockholders over 4 years is $5.6 million, with a median of -$3.3 million recorded in 2023.
  • Peak YoY movement for Net Income towards Common Stockholders: skyrocketed 800.99% in 2024, then crashed 598.17% in 2025.
  • A 4-year view of Net Income towards Common Stockholders shows it stood at -$11.7 million in 2022, then skyrocketed by 213.95% to $13.3 million in 2023, then plummeted by 247.73% to -$19.6 million in 2024, then skyrocketed by 471.25% to $72.9 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Net Income towards Common Stockholders are $72.9 million (Q4 2025), $48.4 million (Q3 2025), and $13.3 million (Q2 2025).